Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8HTR

Crystal structure of Bcl2 in complex with S-9c

8HTR の概要
エントリーDOI10.2210/pdb8htr/pdb
分子名称Apoptosis regulator Bcl-2, 4-[4-[(2~{S})-2-(2-chlorophenyl)pyrrolidin-1-yl]phenyl]-~{N}-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1~{H}-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide (3 entities in total)
機能のキーワードinhibitor, apoptosis
由来する生物種Homo sapiens
タンパク質・核酸の鎖数1
化学式量合計20576.32
構造登録者
Liu, J.,Xu, M.,Feng, Y.,Liu, Y. (登録日: 2022-12-21, 公開日: 2024-05-15, 最終更新日: 2024-06-05)
主引用文献Guo, Y.,Xue, H.,Hu, N.,Liu, Y.,Sun, H.,Yu, D.,Qin, L.,Shi, G.,Wang, F.,Xin, L.,Sun, W.,Zhang, F.,Song, X.,Li, S.,Wei, Q.,Guo, Y.,Li, Y.,Liu, X.,Chen, S.,Zhang, T.,Wu, Y.,Su, D.,Zhu, Y.,Xu, A.,Xu, H.,Yang, S.,Zheng, Z.,Liu, J.,Yang, X.,Yuan, X.,Hong, Y.,Sun, X.,Guo, Y.,Zhou, C.,Liu, X.,Wang, L.,Wang, Z.
Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2.
J.Med.Chem., 67:7836-7858, 2024
Cited by
PubMed Abstract: The approval of venetoclax, a B-cell lymphoma-2 (Bcl-2) selective inhibitor, for the treatment of chronic lymphocytic leukemia demonstrated that the antiapoptotic protein Bcl-2 is a druggable target for B-cell malignancies. However, venetoclax's limited potency cannot produce a strong, durable clinical benefit in other Bcl-2-mediated malignancies (e.g., diffuse large B-cell lymphomas) and multiple recurrent Bcl-2 mutations (e.g., G101V) have been reported to mediate resistance to venetoclax after long-term treatment. Herein, we described novel Bcl-2 inhibitors with increased potency for both wild-type (WT) and mutant Bcl-2. Comprehensive structure optimization led to the clinical candidate BGB-11417 (compound , sonrotoclax), which exhibits strong and inhibitory activity against both WT Bcl-2 and the G101V mutant, as well as excellent selectivity over Bcl-x without obvious cytochrome P450 inhibition. Currently, BGB-11417 is undergoing phase II/III clinical assessments as monotherapy and combination treatment.
PubMed: 38695063
DOI: 10.1021/acs.jmedchem.4c00027
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.6 Å)
構造検証レポート
Validation report summary of 8htr
検証レポート(詳細版)ダウンロードをダウンロード

252091

件を2026-04-15に公開中

PDB statisticsPDBj update infoContact PDBjnumon